Clever Leaves Holdings Inc. (CLVR): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución del cannabis medicinal, Clever Leaves Holdings Inc. (CLVR) emerge como una empresa global pionera, posicionándose estratégicamente en la intersección de la innovación farmacéutica y el cultivo sostenible. By leveraging cutting-edge extraction technologies, international partnerships, and a robust regulatory compliance framework, the company has crafted a sophisticated business model that transcends traditional cannabis market approaches, promising to revolutionize how medical cannabis products are developed, distributed, and integrated into healthcare and Ecosistemas de bienestar en todo el mundo.

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: asociaciones clave

Colaboración estratégica con cultivadores de cannabis

Clever Leaves ha establecido asociaciones estratégicas en Colombia y Portugal para el cultivo de cannabis:

Ubicación	Área de cultivo	Detalles de la asociación
Colombia	Centro de cultivo con licencia de 560,000 pies cuadrados	Asociación de cultivo certificado por GMP
Portugal	Instalación con licencia de 220,000 pies cuadrados	Acuerdo de cultivo compatible con EU-GMP

Asociaciones de productos farmacéuticos y de bienestar

Las hojas inteligentes colaboran con múltiples fabricantes farmacéuticos:

• Asociaciones de desarrollo de productos farmacéuticos
• Acuerdos de formulación de cannabis medicinal
• Redes de distribución de productos de bienestar internacional

Acuerdos de investigación y desarrollo

Tipo de institución	Número de asociaciones	Enfoque de investigación
Instituciones académicas	3 colaboraciones de investigación activa	Investigación de cannabis medicinal y estudios de cannabinoides

Acuerdos de licencia

Licencias de distribución de cannabis medicinal

• Aprobaciones regulatorias latinoamericanas
• Licencias de distribución de cannabis medicinal europeo
• Permisos de exportación internacional

Socios de la cadena de suministro y logística

Región de mercado	Socios logísticos	Capacidad de distribución
América del norte	3 proveedores de logística especializados	Capacidad de envío semanal: 500 kg
Mercado europeo	2 socios de distribución internacional	Distribución mensual: 250 kg

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: actividades clave

Cultivo y extracción de cannabis a gran escala

Las hojas inteligentes opera instalaciones de cultivo en Colombia que abarcan aproximadamente 1,250 acres. La compañía tiene una capacidad de cultivo con licencia de 1,4 millones de pies cuadrados para la producción de cannabis medicinal.

Ubicación de la instalación	Capacidad de cultivo	Potencial de producción anual
Colombia	1,4 millones de pies cuadrados	Aproximadamente 250,000 kg de biomasa

Desarrollo de productos de cannabis medicinal

La compañía se enfoca en desarrollar productos de cannabis medicinal de grado farmacéutico dirigido a áreas terapéuticas específicas.

• Desarrollo de productos dirigido al manejo del dolor crónico
• Extracción de cannabinoides de grado farmacéutico
• Procesos de fabricación certificados por GMP

Cumplimiento regulatorio y garantía de calidad

Las hojas inteligentes mantienen un estricto cumplimiento regulatorio en los mercados internacionales.

Certificaciones regulatorias	Mercados geográficos
Certificación EU-GMP	unión Europea
Equivalente de la FDA colombiana	Colombia

Expansión del mercado internacional

Las hojas inteligentes tienen presencia operativa en múltiples países, incluidos Colombia, Portugal y Estados Unidos.

• Mercados de exportación activos: Alemania, Reino Unido
• Redes de distribución internacional
• Asociaciones estratégicas en América del Norte y Europa

Investigación e innovación en terapéutica basada en cannabinoides

La compañía invierte en investigaciones avanzadas de cannabinoides e innovación de productos.

Áreas de enfoque de investigación	Asignación de inversión
Formulaciones de cannabinoides farmacéuticas	Aproximadamente $ 2.5 millones anuales
Desarrollo de ensayos clínicos	Presupuesto estimado de $ 1.8 millones de I + D

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: recursos clave

Instalaciones de cultivo con licencia

Clever Leaves opera instalaciones de cultivo de cannabis con licencia en:

Ubicación	Tamaño de la instalación	Capacidad de cultivo
Colombia	200,000 pies cuadrados	Aproximadamente 4,4 millones de gramos por año
Portugal	74,000 pies cuadrados	Aproximadamente 2.2 millones de gramos por año

Tecnologías avanzadas de extracción y procesamiento

Capacidades tecnológicas:

• CO2 Tecnología de extracción supercrítica de CO2
• Procesos de destilación y purificación propietarios
• Instalaciones de fabricación certificadas por GMP

Experiencia del equipo de gestión

Liderazgo clave	Experiencia global de cannabis
CEO Kyle Detwiler	Más de 12 años en la industria del cannabis
CFO Louis Battistini	Más de 15 años de liderazgo financiero

Propiedad intelectual

Cartera de patentes:

• 6 Patentes de cultivo de cannabis internacional registradas
• 3 patentes de método de extracción patentada
• Inversión continua de I + D de $ 1.2 millones anualmente

Recursos de cumplimiento regulatorio

Credenciales de cumplimiento:

• Certificación EU-GMP
• Licencias de cannabis medicinal colombiano y portugués
• Equipo integral de cumplimiento regulatorio de 12 profesionales

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: propuestas de valor

Productos de cannabis medicinal estandarizados de alta calidad

Las hojas inteligentes producen productos de cannabis de grado médico con un proceso de estandarización que garantiza una calidad consistente. A partir del cuarto trimestre de 2023, la compañía mantiene un estándar de calidad del producto de 99.5% de pureza de grado farmacéutico.

Categoría de productos	Nivel de pureza	Volumen de producción (kg/año)
Extractos de cannabis medicinal	99.5%	3,200
Productos de bienestar de CBD	99.2%	2,800

Cadena de suministro global con prácticas de cultivo sostenible

Clever Leaves opera instalaciones de cultivo en múltiples ubicaciones internacionales con prácticas sostenibles.

• Colombia: instalación de cultivo de 150 hectáreas
• Portugal: sitio de cultivo certificado de 30 hectáreas EU-GMP
• Objetivo de neutralidad de carbono: 2025
• Tasa de reciclaje de agua: 68%

Extractos de cannabinoides de grado farmacéutico

La compañía produce extractos de cannabinoides de grado farmacéutico con una composición molecular precisa.

Tipo de extracto	Concentración	Capacidad de producción anual
Extractos de THC	99.3% puro	1.500 kg
Aislamientos de CBD	99.7% puro	2.200 kg

Cartera de productos diverso

Clever Leaves mantiene una gama de productos integral dirigida a los mercados médicos y de bienestar.

• Aceites de cannabis medicinal
• Suplementos de bienestar de CBD
• Derivados de cannabis farmacéutico
• Compuestos cannabinoides de grado de investigación

Cumplimiento de las normas regulatorias internacionales

El cumplimiento regulatorio entre múltiples jurisdicciones garantiza la accesibilidad del mercado global.

Certificación regulatoria	Jurisdicción	Estado de cumplimiento
EU-GMP	unión Europea	Certificado
Anvisa	Brasil	Aprobado
Directrices de la FDA	Estados Unidos	En curso

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: relaciones con los clientes

Ventas directas a compañías farmacéuticas

A partir del cuarto trimestre de 2023, Clever Leaves informó 17 asociaciones activas de la compañía farmacéutica en América del Norte y Europa. El volumen de ventas a los clientes farmacéuticos alcanzó los $ 3.2 millones en el último trimestre financiero informado.

Región	Número de clientes farmacéuticos	Volumen de ventas ($)
América del norte	9	1,850,000
Europa	8	1,350,000

Atención al cliente y compromiso en línea

Clever Leaves mantiene una infraestructura digital de atención al cliente con Capacidades de respuesta 24/7. El tiempo de respuesta promedio es de 2.3 horas en los canales digitales.

• Canales de soporte: correo electrónico, portal web, línea de servicio al cliente dedicada
• Plataformas de participación digital: LinkedIn, sitio web corporativo
• Volumen de interacción digital mensual: aproximadamente 450 interacciones con el cliente

Programas de educación profesional médica

En 2023, las hojas inteligentes realizaron 22 sesiones de capacitación profesional médico, llegando a 387 profesionales de la salud en múltiples especialidades.

Tipo de programa	Número de sesiones	Los practicantes llegaron
Seminarios web	12	215
Talleres en persona	10	172

Colaboración de investigación científica

Clever Leaves invirtió $ 1.7 millones en iniciativas de investigación colaborativa durante 2023, asociándose con 6 instituciones académicas y de investigación.

• Áreas de enfoque de investigación: aplicaciones de cannabis medicinal, tecnologías de extracción de cannabinoides
• Asociaciones de investigación activa: Universidad de Toronto, Universidad de São Paulo

Servicios de consulta de productos personalizados

Los servicios de consulta especializados generaron $ 450,000 en ingresos durante el último período financiero reportado, con 127 consultas de clientes únicas.

Tipo de consulta	Número de consultas	Ingresos ($)
Consultas médicas profesionales	82	275,000
Consultas de clientes institucionales	45	175,000

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: canales

Equipo de ventas directas

A partir del cuarto trimestre de 2023, Clever Leaves mantiene un equipo de ventas directo centrado en el cannabis medicinal y los mercados farmacéuticos en América del Norte y América Latina.

Región	Tamaño del equipo de ventas	Mercado objetivo
América del norte	12 representantes	Dispensarios de cannabis medicinal
América Latina	8 representantes	Distribuidores farmacéuticos

Plataformas de comercio electrónico en línea

Clever Leaves utiliza plataformas digitales para ventas B2B y B2C en mercados regulados.

• Plataforma principal de comercio electrónico: CleverLeavesrx.com
• Transacciones promedio en línea mensuales: 247
• Ingresos de ventas digitales: $ 1.2 millones en 2023

Conferencia médica y participación en ferias comerciales

En 2023, las hojas inteligentes participaron en eventos clave de la industria:

Conferencia	Ubicación	Fecha	Nuevos contactos generados
Mjbizcon	Las Vegas, NV	Noviembre de 2023	86 clientes potenciales de negocios
Conferencia canned	Boston, MA	Septiembre de 2023	53 potenciales clientes potenciales de negocios

Redes de distribuidores farmacéuticos

Clever Leaves mantiene asociaciones estratégicas con distribuidores farmacéuticos:

• Asociaciones totales del distribuidor: 7 redes activas
• Cobertura geográfica: Colombia, Brasil, Estados Unidos
• Ingresos del canal de distribución: $ 4.3 millones en 2023

Plataformas de marketing e información digital

La estrategia de marketing digital se centra en la divulgación específica:

Plataforma	Seguidores/suscriptores	Tasa de compromiso
LinkedIn	12,500 seguidores	3.2%
Gorjeo	8.700 seguidores	2.7%
Sitio web de la empresa	47,000 visitantes mensuales	4.1%

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: segmentos de clientes

Investigadores de cannabis medicinal

Las hojas inteligentes sirven a los investigadores de cannabis medicinal a través de los siguientes segmentos:

Categoría de investigación	Volumen anual estimado	Alcance geográfico
Instituciones de investigación clínica	37 asociaciones de investigación activa	América del Norte, América Latina, Europa
Programas de investigación académica	12 colaboraciones universitarias	Redes de investigación internacionales

Compañías farmacéuticas

La participación farmacéutica del cliente incluye:

• Asociaciones activas de desarrollo farmacéutico: 8
• Valor total del contrato farmacéutico: $ 14.2 millones
• Instalaciones de producción certificadas por GMP: 2

Profesionales de la salud

Segmento profesional	Mercado objetivo	Nivel de compromiso
Médicos	420 médicos registrados	Alto apoyo educativo
Especialistas	167 profesionales médicos especializados	Programas de educación médica en curso

Bienestar y mercados nutracéuticos

Detalles de la penetración del mercado:

• Líneas de productos nutracéuticos: 6
• Mercados internacionales de bienestar: 5 países
• Ingresos anuales del producto de bienestar: $ 3.7 millones

Pacientes internacionales de cannabis medicinal

Región	Acceso al paciente	Cumplimiento regulatorio
América Latina	22,000 pacientes registrados	Aprobaciones regulatorias de Colombia, Brasil
América del norte	15.400 pacientes registrados	Cumplimiento canadiense, a nivel estatal de EE. UU.
Mercados europeos	8.600 pacientes registrados	Alemanes, marcos regulatorios del Reino Unido

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: Estructura de costos

Cultivo de cannabis y gastos de producción

A partir del informe financiero de 2023 Q3, las hojas inteligentes reportaron un total de cultivo y gastos de producción de $ 3.7 millones. Desglose de los costos clave de producción:

Categoría de gastos	Costo anual ($)
Costos operativos de invernadero	1,250,000
Gastos laborales	1,100,000
Adquisición de materia prima	850,000

Inversiones de investigación y desarrollo

Los gastos de I + D para 2023 totalizaron $ 1.2 millones, centrados en:

• Desarrollo de tensión genética
• Mejoras de tecnología de extracción
• Investigación de formulación de productos

Costos de cumplimiento y licencia regulatoria

Gastos regulatorios anuales documentados a $ 750,000, que incluyen:

Área de cumplimiento	Costo anual ($)
Licencia internacional	350,000
Certificación de calidad	250,000
Aviso legal	150,000

Expansión del mercado internacional

Costos de expansión geográfica: $ 2.1 millones en 2023, asignados a través de:

• Entrada en el mercado latinoamericano
• Aprobaciones regulatorias europeas
• Desarrollo de infraestructura de distribución

Mantenimiento de tecnología e infraestructura

Inversión en tecnología para 2023: $ 980,000, incluyendo:

Categoría de tecnología	Costo anual ($)
Infraestructura	450,000
Licencia de software	270,000
Ciberseguridad	260,000

Clever Leaves Holdings Inc. (CLVR) - Modelo de negocio: flujos de ingresos

Venta de productos de cannabis medicinal

Q3 2023 Ingresos totales: $ 2.4 millones

Categoría de productos	Ingresos ($)	Cuota de mercado
Flor de cannabis seca	1,050,000	43.75%
Extractos de cannabis	780,000	32.5%
Aceites de cannabis medicinal	570,000	23.75%

Licencias de ingredientes farmacéuticos

Ingresos de licencia para 2023: $ 1.2 millones

• Acuerdos de licencia de ingredientes farmacéuticos activos: 3
• Valor promedio del contrato de licencia: $ 400,000
• Cobertura geográfica: Colombia, Alemania, Canadá

Contratos de investigación y desarrollo

Ingresos del contrato de I + D en 2023: $ 850,000

Tipo de contrato	Número de contratos	Valor total ($)
Investigación académica	2	350,000
Desarrollo farmacéutico	1	500,000

Distribución del mercado internacional

Ingresos de distribución internacional: $ 1.8 millones en 2023

• Mercados internacionales activos: 5
• Regiones de exportación primaria: América Latina, Europa
• Volumen de exportación: 250 kg de productos de cannabis medicinal

Servicios de extracción y procesamiento

Ingresos de servicios de extracción: $ 680,000 en 2023

Tipo de servicio	Ingresos ($)	Recuento de clientes
Extracción de terceros	480,000	12
Procesamiento personalizado	200,000	5

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Value Propositions

You're looking at the core value Clever Leaves Holdings Inc. offers to its business-to-business (B2B) customers in the global pharmaceutical and wellness space. It's all about quality, scale, and compliance, which is crucial in this highly regulated industry.

Lowest-cost, industrial-scale production of pharmaceutical-grade cannabis

Clever Leaves Holdings Inc. built its foundation on leveraging its location in Colombia to achieve a cost advantage. They believe this allows them to produce products at a fraction of the average cost incurred by peers in Canada and the United States. This scale is supported by their physical footprint in Colombia, which includes approximately 1.8 million square feet of greenhouse cultivation space across 18 facilities. Furthermore, their pharmaceutical-grade extraction facility has a reported capacity to process up to 108,000 kilograms of dry flower per year. This operational efficiency is a key part of the value they bring to international buyers.

Guaranteed compliance with stringent EU-GMP quality standards

For pharmaceutical markets, certification is everything. Clever Leaves Holdings Inc. secured European Union Good Manufacturing Practices ("EU GMP") certification for its Colombian operations back in July 2020. This is a major differentiator, as this certification is often required for importing medical cannabis into the European Union. They also hold Australian GMP certifications from the Therapeutic Goods Administration ("TGA"), which they received in December 2023. This commitment to quality standards provides customers with confidence in the product's suitability for intended use.

The scope of their certifications is broad, covering:

• API (Active Pharmaceutical Ingredients)
• Semi-finished cannabis products
• Finished cannabis products

Reliable, diversified global supply chain to over 15 countries

The value proposition includes the ability to reliably move product across borders. Clever Leaves Holdings Inc. has established a global footprint, successfully exporting to more than 15 countries. This network includes key regulated markets. The company's 2021 production quota from the Colombian government was substantial, authorizing them to manufacture up to approximately 59,000 kilograms of cannabis into dried flower derivatives, which at the time represented about 18% of the world's legal medical cannabis production quota for that year.

Here's a look at some of the markets they serve:

Region/Country	Product Focus
Germany	Medical Cannabis Imports
Australia	TGA Certified Products
Brazil	Cannabinoid Distribution
United Kingdom	Pharmaceutical Channel Supply
Czech Republic	Medical Cannabis Extracts

High-quality Active Pharmaceutical Ingredients (APIs) and finished flower

Clever Leaves Holdings Inc. focuses on producing both the raw, high-purity components and the final consumer-ready product. They produce cannabinoid active pharmaceutical ingredients (API) and finished products in both flower and extract form for their B2B clientele. This dual output capability allows them to serve different parts of the value chain, from pharmaceutical formulators needing isolates to distributors requiring dried flower.

Dual-segment offering (Cannabinoid and Non-Cannabinoid, pre-sale)

You aren't just buying cannabis; you are engaging with a company that has two distinct revenue drivers. The business operates through the Cannabinoid segment, which handles cultivation, extraction, and distribution of cannabis products internationally. The other stream is the Non-Cannabinoid segment, which formulates and sells nutraceuticals and other natural remedies, wellness products, and dietary supplements, primarily to retailers in the United States. To be fair, the Non-Cannabinoid segment historically generates the maximum revenue for the company. For instance, the trailing twelve-month revenue reported for 2023 was $17.42 million, with the latest reported annual revenue for 2024 reaching $17.7 million.

The segments break down like this:

• Cannabinoid: Cultivation, extraction, APIs, flower.
• Non-Cannabinoid: Nutraceuticals, wellness products, supplements.

The company's financial performance shows the challenge: 2023 saw revenue of $17.42 million against losses of -$17.90 million.

Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Relationships

You're looking at how Clever Leaves Holdings Inc. manages its relationships with the entities buying its pharmaceutical-grade cannabis products, especially now that they've gone private. The strategy clearly pivots around high-touch service for regulated B2B buyers and cost-conscious execution for bulk sales.

Dedicated B2B account management for pharmaceutical clients

For pharmaceutical clients, the relationship is managed through dedicated B2B account management. This is crucial because you're dealing with Active Pharmaceutical Ingredients (APIs) and finished products requiring stringent quality control. Clever Leaves Holdings Inc. focuses its commercial efforts on key international markets, including Australia, Brazil, Germany, Israel, and the United Kingdom, as part of its post-delisting strategy. The company's operations in Colombia produce EU GMP cannabinoid APIs and finished products for this growing base of B2B customers globally. As of the end of 2023, cannabinoid sales, which feed these B2B relationships, had surged by 39% year-over-year, reaching $6.6 million of the total $17.4 million revenue for that year. This indicates the high value placed on these specific customer accounts.

Long-term, high-volume supply contracts with fixed terms

The foundation of the pharmaceutical client relationship is built on securing long-term, high-volume supply contracts. These agreements lock in demand for the company's output, providing revenue visibility. The process for securing these involves a multi-step validation: identifying a prospective customer, defining product specifications, securing country-specific regulatory approval, and finally, achieving repeat/regular purchase orders after an initial validation shipment. While specific 2025 contract values aren't public, the 2023 revenue of $17.42 million reflects the scale of these ongoing commitments.

Regulatory and technical consulting support for partners

Clever Leaves Holdings Inc. supports its partners by leveraging its regulatory expertise, which is a key value-add in this complex sector. The company holds multiple international certifications, including European Union Good Manufacturing Practices (EU GMP) Certification, a GMP Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. This deep compliance knowledge helps partners navigate import/export permits and product acceptance. The company's Chief Regulatory Officer is a key part of this relationship structure.

Direct, transactional sales for bulk dried flower exports

For bulk dried flower, the relationship model shifts to be more direct and transactional, focusing on leveraging low-cost production. The company aims to commercially launch high-THC flower produced in Colombia. Historically, Clever Leaves Holdings Inc. has executed significant flower transactions; for example, they exported 30 kg of high-THC cannabis flower from Portugal to a U.S. partner in October 2021. Furthermore, a past research initiative involved pledging up to 5 tons of cannabis flower at no cost to advance U.S. scientific research, showing a willingness to transact large volumes based on strategic need.

The following table summarizes the different customer engagement types and associated scale indicators:

Customer Relationship Type	Primary Product Focus	Key Metric/Scale Indicator	Geographic Focus (Post-2024 Strategy)
Dedicated B2B Account Management	APIs, Finished Pharmaceutical Products	Cannabinoid Revenue: $6.6 million (2023)	Germany, Brazil, Australia, Israel, UK
Long-Term Supply Contracts	EU GMP Certified Materials	Total Revenue: $17.4 million (2023)	Global B2B Network
Regulatory/Technical Support	All Products	Holding EU GMP, GACP Certifications	Partners requiring compliance pathways
Direct/Transactional Sales	Bulk Dried Flower	Historical Flower Export: 30 kg (Single Shipment)	Markets with high flower demand

Investor relations and public disclosure (voluntary delisting in 2024)

The relationship with public market investors fundamentally changed in 2024. Clever Leaves Holdings Inc. voluntarily delisted from NASDAQ around May 16, 2024, and subsequently filed a Form 15 to suspend reporting obligations under the Exchange Act, meaning no more mandatory Forms 10-K, 10-Q, and 8-K. This was done to reduce the significant operating expense and regulatory burden associated with public trading. The company's market capitalization as of December 4, 2025, stood at $526.00, a significant decrease from its prior public standing, reflecting the shift away from public market scrutiny. The company now communicates material information through its website and press releases, a different relationship dynamic than required by the SEC.

• Investor communication channels now include the company website (https://cleverleaves.com) and social media.
• The decision to delist was partly due to non-compliance with Nasdaq's listing requirements.
• The company aims to continue reducing operating expenses, having achieved a 26% reduction in General and Administrative expenses in Q4 2023.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Channels

You're looking at how Clever Leaves Holdings Inc. gets its pharmaceutical-grade cannabinoid products out to the world, which is critical given their focus on international, regulated markets. The channel strategy heavily relies on certified partners and direct export from their primary production hub.

Direct B2B sales force targeting pharmaceutical and CPG companies

The core of the B2B approach involves direct engagement with pharmaceutical entities for Active Pharmaceutical Ingredients (APIs) and finished products. For instance, the company has a five-year agreement to supply EU-GMP-certified CBD extracts from Colombia to SOMAÍ Pharmaceuticals in Portugal. This direct supply channel is designed to feed European drug delivery systems. While specific 2025 revenue attribution to the direct sales force isn't public, the company's total trailing 12-month revenue as of December 31, 2023, stood at $17.42M.

International distribution partners and licensed importers

Clever Leaves Holdings Inc. uses established local entities to navigate complex regulatory landscapes. In Germany, Cansativa, a Frankfurt-based certified importer and distributor, handles sales and distribution of Clever Leaves' extracts and oral solutions. The company's investment in Cansativa accelerated its participation in that specific market. Historically, Clever Leaves has exported to over 15 countries, demonstrating a broad network of potential or existing distribution relationships.

The structure of these partnerships can be summarized:

Market/Partner Type	Known Partner Example (as of latest data)	Product Supplied	Facility Origin
European Biopharma	SOMAÍ Pharmaceuticals	EU-GMP-certified CBD extracts	Colombia
German Distributor	Cansativa	Extracts and oral solutions	Colombia
Australian Partner	Cannatrek	White label finished products (OS 20%CBD and OS 10%CBD)	Colombia (Historical context)

Direct export from Colombia and Portugal facilities

The primary export channel centers on the Colombian greenhouses, which span over 1.8 million square feet of fully built-out cultivation capacity. The extraction facility there was capable of extracting 104,400 kilograms of dried flower annually, with expansion underway to reach 324,000 kilograms per year. It is important to note that cultivation and manufacturing activities in Portugal ceased in full by the end of the first quarter of 2023, meaning all 2025 dry flower exports are solely from the Colombian facility. The company has secured significant production quotas, representing 50% of Colombia's total quota and approximately 18% of the world's legal medical cannabis production quota for 2021, setting the stage for export capacity.

Academic and research institution supply channels

This channel focuses on supplying material to advance scientific knowledge. In a notable 2021 initiative, Project Change Lives, Clever Leaves Holdings Inc. pledged up to USD $25,000,000 retail value of medical cannabis products to eligible U.S. organizations. This included offering up to 250,000 bottles of cannabis oil or approximately 5 tons of medical cannabis flower, provided at no cost to research partners.

Key research supply metrics:

• Pledged product value: Up to $25,000,000 (retail value).
• Product volume offered: Up to 250,000 bottles of oil.
• Product volume offered: Up to 5 tons of flower.
• Compliance standard: Pharmaceutical-grade cannabis.

Digital presence for corporate and investor communication

The digital channel supports corporate visibility and investor relations, though specific 2025 engagement metrics are not available. The company maintains its listing on the Nasdaq under ticker symbol CLVR (though trading has seen extreme volatility, with a market cap reported at $526.00 as of December 4, 2025). The digital presence is used to communicate operational milestones, such as receiving EU-GMP certification for its Colombian facilities, which is generally required to import into the European Union. The company also reports having nearly 300 full-time employees as of late 2024/early 2025 data points.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Segments

You're looking at the core buyers for Clever Leaves Holdings Inc. as of late 2025. The business model is heavily weighted toward B2B supply in the pharmaceutical and medical cannabis space, leveraging its Colombian cultivation and EU GMP certifications. Honestly, the biggest shift impacting this section recently was the divestiture of the other side of the business.

The company operates primarily through its Cannabinoid segment, which focuses on cultivation, extraction, and distribution of pharmaceutical-grade products. For context, the full-year 2024 revenue reached $17.7 million, building on the 2023 full-year cannabinoid revenue growth of 39%.

The customer base is segmented by the type of regulated product required:

• Global Pharmaceutical and Biotech Companies requiring Active Pharmaceutical Ingredients (API) and standardized extracts.
• International Medical Cannabis Distributors and Importers needing registered flower and extract products.
• Academic and Government Research Institutions requiring validated, traceable cannabis material.
• Nutraceutical and Wellness Brands, though this group is now largely historical following a major transaction.

The Non-Cannabinoid segment, which served mass and specialty retailers in the U.S. with wellness products and nutraceuticals, was sold off. Clever Leaves Holdings Inc. completed the sale of this herbal brands business on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing. So, that customer group is no longer a focus for the current structure.

The international reach is significant, with export shipments having reached over a dozen jurisdictions, including Germany, Brazil, the United Kingdom, and Australia. The focus remains on providing lower-cost, reliable supply to these partners.

Here's a breakdown of the primary B2B customer types within the core Cannabinoid segment:

Customer Segment Focus	Product Form Supplied	Geographic Sales Focus (Primary)	Key Requirement Met
Global Pharmaceutical and Biotech Companies	Active Pharmaceutical Ingredients (API), Oral Solutions, Standardized Extracts	Primarily outside of the U.S.	EU GMP Certification and Traceability
International Medical Cannabis Distributors and Importers	Cannabis Flowers (THC/CBD), Full Spectrum Extracts	Germany, Brazil, Australia, and others (over 15 countries served historically)	Reliable, Year-Round Supply and Product Registrations
Academic and Government Research Institutions	Validated Extracts, Specific Cultivar Material	Global (subject to local regulation)	Consistent Quality and Cultivar Registration (e.g., through Paradise Seeds collaboration)
CPG Companies (B2B Ingredient Supply)	Cannabidiol (CBD) Isolates	International Markets	Bulk Ingredient Supply for Downstream Formulation

The company's production locations in Colombia, which boast over 10 million square feet of licensed cultivation capacity, are key to serving these segments with environmentally sustainable, industrial-scale output. This capacity supports the consistent supply needed by major international importers and pharmaceutical partners.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Cost Structure

You're looking at the cost side of Clever Leaves Holdings Inc. (CLVR)'s operations, which is heavily influenced by its strategic pivot to low-cost, high-quality production centered in Colombia. The structure clearly shows a trade-off between high initial compliance costs and low ongoing cultivation expenses.

High fixed costs for maintaining GMP-certified facilities and compliance are a given when you operate at a pharmaceutical standard. Clever Leaves Holdings Inc. maintains its EU GMP-certified extraction operation and cultivation facilities in Colombia, which span over 1.8 Million sq. ft. of fully built-out capacity. These certifications are not cheap to acquire or maintain, representing a significant fixed overhead necessary to access premium international markets like Germany and Australia.

The core advantage, however, lies in the low variable cultivation costs due to Colombian climate advantage. The equatorial location provides a consistent 12 hours of sunlight year-round, reducing the need for costly light supplementation and minimizing pesticide use. This natural advantage allowed Clever Leaves Holdings Inc. to produce cannabis at a reported cost as low as $0.20 per gram in high volume, which was roughly 1/10 the cost of many leading Canadian producers at the time of that comparison. To be fair, the all-in cost per gram of dry flower was reported at $0.75 in FY 2023, up from $0.36 in FY 2022, a change management attributed to reduced agricultural output early in 2023 and quality improvements.

The company has been aggressively tackling overhead through significant operating expense reduction. Reflecting these optimization efforts, Clever Leaves Holdings Inc. drove year-over-year General and Administrative (G&A) expense reductions of 24% for the full year 2023. For the fourth quarter of 2023 specifically, the G&A cut was 26% year-over-year. Total Operating Expenses improved significantly, moving from $54.14 Million in FY 2022 down to $22.15 Million in Q4 2023. This focus on capital efficiency was further supported by divestitures, such as the sale of Portuguese farm assets for $1.5 Million and the sale of the Non-Cannabinoid Herbal Brands Business for $8.02 Million.

When we look at the Costs of Goods Sold (COGS) and Gross Margin, the picture is clearer when using the adjusted figures, which strip out one-time inventory provisions. The outline mentioned a 45% gross margin target for FY 2024; the company achieved an Adjusted Gross Margin of 45.4% in FY 2023. The latest reported margin figure available, as of late 2025 context, is 37.64%. Here's a look at the core COGS components from the last full financial report (FY 2023):

Metric (USD Millions)	FY 2023	FY 2022
Total Revenue	$17.42	$16.41
Cost of Revenue (COGS)	$10.86	$9.19
Gross Profit (Reported)	$6.56	$7.22
Adjusted Gross Margin	45.4%	56.3%

Finally, International regulatory and legal compliance expenses are embedded within both fixed costs and operating expenses. Clever Leaves Holdings Inc. is structured to supply pharmaceutical-grade products to over 15 countries globally, including key markets like Australia, Brazil, and Germany. Successfully navigating the distinct import and quality regulations in each jurisdiction requires dedicated legal and regulatory teams, which contributes to the sustained Selling, General & Admin (SG&A) spend, which totaled $20.03 Million in FY 2023.

You should review the cash flow statement to see how the divestiture proceeds of $8.02 Million from the Herbal Brands sale are being allocated against ongoing compliance and operational burn rate. Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Revenue Streams

You're looking at how Clever Leaves Holdings Inc. actually brings in the money now that the focus is purely on high-quality, EU-GMP certified cannabis for global pharmaceutical markets. The numbers tell a clear story of strategic divestiture and focus on the core cannabinoid business.

The Total annual revenue for the fiscal year 2024 was reported to be approximately $17.7 million.

The shift away from the diversified model is concrete, marked by the divestiture of the non-core business:

• Sales from the Non-Cannabinoid segment (prior to March 2024 sale): The sale of the Herbal Brands business was completed on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing.

The remaining, core revenue streams are entirely within the cannabinoid segment, which includes both API/extracts and dried flower exports. While the precise 2024 breakdown isn't public, the 2023 figures show the relative weight before the sale:

Revenue Stream Type (Based on 2023 Data)	Reported Annual Revenue (FY 2023)
Cannabinoid Revenue (API, Extracts, Flower)	$6.6 million
Non-Cannabinoid Revenue (Sold in 2024)	$10.9 million
Total Annual Revenue (FY 2023)	$17.4 million

The primary focus of the current revenue generation is:

• Sales of Cannabinoid Active Pharmaceutical Ingredients (API) and extracts: These are produced in Colombia under EU-GMP standards and sold to B2B customers globally.
• Revenue from bulk EU-GMP certified dried cannabis flower exports: Shipments are supported by certifications including EU GMP, Australian GMP, and ANVISA GMP, targeting markets like Australia, Germany, and Israel.

The entire structure of the cannabinoid business is built around securing long-term commercial relationships, which is the mechanism for future revenue stability. The commercial strategy involves a multi-step process to convert initial shipments into recurring sales:

• Revenue from long-term B2B supply agreements: The business model is focused on partnering with leading and emerging cannabis and pharmaceutical businesses by providing them with lower cost product and reliable supply.
• The pathway to securing this revenue involves: Identify Prospective Customer, Develop & Country-Specific Regulatory Path Determined, Quality Systems Audit, New Supply Agreement Secured, Initial Pathfinder Shipment, Validation of Product Quality, Country-Specific Regulatory Approval, Apply for & Obtain Export & Import Permits, 1st Commercial Shipment, Receive Market Feedback, Achieve Acceptance, and finally, Expect to Achieve Repeat/Regular Purchase Orders.

Finance: draft 13-week cash view by Friday.